Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design

J Med Chem. 2017 Nov 22;60(22):9205-9221. doi: 10.1021/acs.jmedchem.7b01039. Epub 2017 Nov 9.

Abstract

Dysregulation of anaplastic lymphoma kinase (ALK) has been detected in nonsmall cell lung cancer (NSCLC) in the form of EML4-ALK fusion. Secondary mutations opposing activity of the first-generation ALK inhibitor crizotinib came into existence, requiring mutation-targeting drug discovery for the powerful second-line treatment. In this study, we report 4-phenoxyquinoline-based inhibitors that overcome crizotinib resistance to ALK L1196M, discovered by the fragment-growing strategy. The protonation of 4-aminoquinoline core could interrupt the ability the N atom of quinoline to act as a hydrogen bond acceptor; therefore, the pKa and calculated ionization pH values of relevant pyridine-based core moieties were carefully analyzed. The replacement of amine linkage with ether resulted in single-digit nanomolar range inhibitors. The inhibitors exhibited significant antiproliferative effects on H2228 CR crizotinib-resistant cells by decreasing PI3K/AKT and MAPK signaling. This work constitutes the first example for systematic investigation of the effect of ionization pH on activity in this system.

MeSH terms

  • Amino Acid Substitution
  • Anaplastic Lymphoma Kinase
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Carbazoles / pharmacology
  • Cell Line, Tumor
  • Crizotinib
  • Drug Design
  • Drug Resistance, Neoplasm
  • ERG1 Potassium Channel / antagonists & inhibitors
  • Humans
  • Kinetics
  • Piperidines / pharmacology
  • Pyrazoles / pharmacology
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Quinolines / administration & dosage
  • Quinolines / chemistry
  • Quinolines / pharmacokinetics
  • Quinolines / pharmacology*
  • Rats
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / genetics
  • Signal Transduction
  • Structure-Activity Relationship
  • Sulfones / pharmacology

Substances

  • Antineoplastic Agents
  • Carbazoles
  • ERG1 Potassium Channel
  • KCNH2 protein, human
  • Piperidines
  • Pyrazoles
  • Pyridines
  • Pyrimidines
  • Quinolines
  • Sulfones
  • Crizotinib
  • ALK protein, human
  • Alk protein, rat
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
  • ceritinib
  • alectinib